BG106729A - Натрий-водород обменен тип 1 инхибиторни кристали - Google Patents

Натрий-водород обменен тип 1 инхибиторни кристали Download PDF

Info

Publication number
BG106729A
BG106729A BG106729A BG10672902A BG106729A BG 106729 A BG106729 A BG 106729A BG 106729 A BG106729 A BG 106729A BG 10672902 A BG10672902 A BG 10672902A BG 106729 A BG106729 A BG 106729A
Authority
BG
Bulgaria
Prior art keywords
tissue
rel
crystal
pharmaceutical composition
administered
Prior art date
Application number
BG106729A
Other languages
Bulgarian (bg)
English (en)
Inventor
Lyne BROSTROM
Terrence CONNOLLY
Zheng Li
Susan ORRILL
Bharat Shah
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106729A publication Critical patent/BG106729A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG106729A 1999-10-29 2002-05-20 Натрий-водород обменен тип 1 инхибиторни кристали BG106729A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (1)

Publication Number Publication Date
BG106729A true BG106729A (bg) 2002-12-29

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106729A BG106729A (bg) 1999-10-29 2002-05-20 Натрий-водород обменен тип 1 инхибиторни кристали

Country Status (44)

Country Link
EP (1) EP1224179B1 (zh)
JP (1) JP2003512455A (zh)
KR (1) KR100464526B1 (zh)
CN (2) CN1205205C (zh)
AP (1) AP2002002493A0 (zh)
AR (1) AR029402A1 (zh)
AT (1) ATE271047T1 (zh)
AU (1) AU778573B2 (zh)
BG (1) BG106729A (zh)
BR (1) BR0015275A (zh)
CA (1) CA2389020A1 (zh)
CO (1) CO5271714A1 (zh)
CZ (1) CZ20021332A3 (zh)
DE (1) DE60012208T2 (zh)
DK (1) DK1224179T3 (zh)
DZ (1) DZ3463A1 (zh)
EA (1) EA004937B1 (zh)
EE (1) EE200200227A (zh)
ES (1) ES2222923T3 (zh)
GE (1) GEP20043222B (zh)
GT (1) GT200000180A (zh)
HK (1) HK1048472B (zh)
HR (1) HRP20020366B1 (zh)
HU (1) HUP0204009A3 (zh)
IL (1) IL148581A0 (zh)
IS (1) IS6302A (zh)
MA (1) MA26840A1 (zh)
MX (1) MXPA02004358A (zh)
NO (1) NO20021821L (zh)
NZ (1) NZ517738A (zh)
OA (1) OA12080A (zh)
PA (1) PA8505501A1 (zh)
PE (1) PE20010764A1 (zh)
PL (1) PL354869A1 (zh)
PT (1) PT1224179E (zh)
SI (1) SI1224179T1 (zh)
SK (1) SK5312002A3 (zh)
SV (1) SV2002000209A (zh)
TN (1) TNSN00210A1 (zh)
TR (1) TR200201167T2 (zh)
UA (1) UA72002C2 (zh)
WO (1) WO2001030759A2 (zh)
YU (1) YU31502A (zh)
ZA (1) ZA200203295B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
MXPA03006872A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Etanolatos del inhibidor del intercambiador de sodio-hidrogeno de tipo 1.
BR0307195A (pt) * 2002-01-30 2004-11-03 Pfizer Prod Inc Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056729B1 (en) * 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
NZ517738A (en) 2005-06-24
PA8505501A1 (es) 2003-09-05
GT200000180A (es) 2002-04-11
TR200201167T2 (tr) 2002-08-21
KR100464526B1 (ko) 2005-01-03
ATE271047T1 (de) 2004-07-15
OA12080A (en) 2003-08-25
EE200200227A (et) 2003-06-16
CN1636991A (zh) 2005-07-13
SI1224179T1 (en) 2004-10-31
PL354869A1 (en) 2004-03-08
BR0015275A (pt) 2002-07-16
AP2002002493A0 (en) 2002-06-30
CZ20021332A3 (cs) 2002-10-16
WO2001030759A2 (en) 2001-05-03
HUP0204009A3 (en) 2004-07-28
HK1048472A1 (en) 2003-04-04
IS6302A (is) 2002-03-15
IL148581A0 (en) 2002-09-12
GEP20043222B (en) 2004-04-26
ES2222923T3 (es) 2005-02-16
CN1384829A (zh) 2002-12-11
EA200200416A1 (ru) 2002-10-31
CA2389020A1 (en) 2001-05-03
NO20021821D0 (no) 2002-04-18
MXPA02004358A (es) 2002-11-07
SK5312002A3 (en) 2003-01-09
DZ3463A1 (fr) 2001-05-03
AU7441500A (en) 2001-05-08
ZA200203295B (en) 2003-06-25
HRP20020366B1 (en) 2005-04-30
AU778573B2 (en) 2004-12-09
HRP20020366A2 (en) 2004-02-29
CO5271714A1 (es) 2003-04-30
CN1205205C (zh) 2005-06-08
YU31502A (sh) 2004-12-31
WO2001030759A3 (en) 2001-09-13
SV2002000209A (es) 2002-07-16
PT1224179E (pt) 2004-10-29
HUP0204009A2 (hu) 2003-03-28
UA72002C2 (en) 2005-01-17
JP2003512455A (ja) 2003-04-02
KR20020040918A (ko) 2002-05-30
MA26840A1 (fr) 2004-12-20
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
DE60012208D1 (de) 2004-08-19
EP1224179B1 (en) 2004-07-14
DE60012208T2 (de) 2005-07-21
EP1224179A2 (en) 2002-07-24
EA004937B1 (ru) 2004-10-28
HK1048472B (zh) 2005-09-16
TNSN00210A1 (fr) 2005-11-10
NO20021821L (no) 2002-04-18
DK1224179T3 (da) 2004-10-25

Similar Documents

Publication Publication Date Title
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
EA015516B1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
EA003603B1 (ru) N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
US5397798A (en) Benzamide and sulfonamide hypoglycemic agents
BG106729A (bg) Натрий-водород обменен тип 1 инхибиторни кристали
JP3712529B2 (ja) ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩
BG107139A (bg) Инхибитор тип 1 (nнe-1) обменящ натрий - водород
BG109771A (bg) 3-(((4-фенил)-пиперазин-1-ил)-алкил)-3-алкил-1,3-дихидро-2н-индол-2-он производни и техни съединения за лечение на заболявания на централната нервна система
AU779106B2 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
KR20040046420A (ko) 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
AU2005201428A1 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
US20010051634A1 (en) Sodium-hydrogen exchanger type 1 inhibitor